Vamorolone is a first-in-class drug that borrows some activities of corticosteroids (anti-inflammatory activity via NFkB repression), while adding new activities not seen with corticosteroids (eplerenone-like activity; membrane stabilization activity). Vamorolone hopes to retain the beneficial anti-inflammatory and muscle strengthening aspects of corticosteroids, while decreasing some of the undesirable side effects (bone fragility, stunted growth, insulin resistance, mood changes, delay of puberty and others). Vamorolone is given as an oral liquid flavored formulation at home daily.
Santhera currently has a New Drug Application (NDA) under review with the FDA with a target date of October 26th, 2023. Learn more here.
This program is sponsored by Santhera Pharmaceuticals and has been partially funded by Parent Project Muscular Dystrophy.
JUNE 2021 | Santhera Pharmaceuticals Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
MAR 2021 | Santhera Pharmaceuticals Duchenne Drug Development UpdateSanthera Pharmaceuticals joined Parent Project Muscular Dystrophy (PPMD) for a webinar on March 24, 2021 to provide an update to the community about the investigational therapy vamorolone, the use of steroids to treat Duchenne muscular dystrophy, clinical trials for vamorolone, and development timelines. |
JULY 2020 | ReveraGen Presents at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library |
JUNE 2019 | Paula Clemmons, MD Presents at the PPMD 2019 Annual Conference |
JAN 2019 | Webinar: Vamorolone Clinical Trials in DuchenneOn January 30, 2019, ReveraGen joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the vamorolone drug development program for Duchenne, including results showing improved muscle function in completed clinical trials in 48 Duchenne boys, and a description of an ongoing clinical trial of 120 Duchenne boys that is accepting new patients at 30 sites internationally. |
JUNE 2018 | ReveraGen Presents at the PPMD 2018 Annual Conference |
JAN 2017 | Webinar: Vamorolone (VBP15) Clinical Trials in DuchenneOn January 18, 2017, PPMD was joined by ReveraGen BioPharma for a webinar discussion on vamorolone (VBP15) clinical trials in Duchenne. |
